HANSOH PHARMA

3692
33.9001.51% ( -0.520 )
Delay Closed: Nov 16, 16:08:11

Overview

HANSOH PHARMA (3692)

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical product...

Open
34.860
High
34.860
Low
33.280
Prev. Close
34.420
Volume
10.37M
Turnover
350.44M
Avg Price
33.785
Bid/Ask Ratio
-75.61%
Amplitude
4.59%
52wk High
43.735
Volume Ratio
0.97
Turnover Ratio
0.17%
52wk Low
27.575
HK Mkt Cap
205.57B
Market CapHKD
205.57B
P/ETTM
26.74
P/EDynamic
20.97
P/EStatic
--
EPSTTM
1.27
EPSDynamic
1.62
EPSStatic
--
BVPS
7.17
P/B
4.73
HK Shares
6.06B
Dividend YieldTTM
1.43%
DividendTTM
0.485
Shares
6.06B
Min lot size
2,000
Currency
HKD

HANSOH PHARMA Analyst Rating

View more

Forecast & Rating

Nov 13, 2026
Price forecast
HK$48.4342.85%
Forecast & RatingStrong buy
23analysts
  • Strong buy73.91%
  • Buy26.09%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 4

    Overnight a Democratic sweep of Congress lifted the Hang Seng Index about 300 points with biotech leading, and Hansoh Pharma turned an opening dip at HK$32.50 into a one-way afternoon advance, closing up 6.82% at HK$34.12 after touching HK$34.18 at 15:52 against a HK$32.28 morning low. UBS kept its Buy rating with a HK$50.8 target after positive Mo-Rez data in platinum-resistant ovarian cancer, while the company's Ris-Rez cut progression or death risk by 67% in a Phase 3 osteosarcoma trial. Q2 2026 revenue of HK$4.80 billion rose 17.75% year on year and net profit of HK$2.46 billion rose 43.17% at a 51.28% margin, leaving the stock above its MA20 of HK$32.42 and MA60 of HK$33.61, yet it is still down 6.37% year to date and 22.84% below the HK$44.22 52-week high. Domestic competition in innovative drugs remains a variable.

  2. Oct, 23

    Hansoh Pharma rebounded from an early dip after an expanded ADC partnership with Roche and ESMO data drew fresh coverage: the stock slipped to HK$31.82 shortly after the open, climbed to an intraday HK$33.60 in the afternoon and closed 3.58% higher at HK$33.00 on HK$692 million turnover. Goldman Sachs, CICC and CMBI followed through, with CMBI raising its target price to HK$50.54 while CICC kept HK$52 with an outperform rating. Q2 2026 results corroborate the move: revenue of HK$4.80 billion (+17.75% yoy), net profit of HK$2.46 billion (+43.17%), a 51.28% net margin and 22.55% ROE. Yet the close sits near the HK$33.02 MA20 but below the HK$33.57 MA60, down 9.44% year-to-date and 25.37% below the HK$44.22 52-week high, while the Hang Seng Index fell 717 points below 23,000 that day.

  3. Oct, 22

    Hansoh Pharmaceutical opened at HK$34.38 and slid through the session to close at HK$31.86, down 7.33%, as the Hang Seng Index fell below 23,000 intraday and innovative-drug names declined almost across the board, pulling the stock into a market-wide de-risking move; after early strength it drifted from HK$34.80 to a 13:49 BJ low of HK$31.70. Broker actions stayed constructive — CMBI set a HK$50.54 target citing the Roche partnership and ESMO data, JPMorgan set HK$50, and UBS reiterated its buy rating — yet none offset the index-level selling. The earnings backdrop contrasts with the tape: Q2 2026 revenue was HK$4.796bn, up 17.75% yoy, and net profit HK$2.459bn, up 43.17%, while the shares have broken below the MA20 of HK$33.12 and MA60 of HK$33.58 and are down 12.57% year-to-date, still 13.54% above the 52-week low of HK$28.06. At 25.13x PE, turnover of just HK$472mn and a 0.24% turnover rate point to limited buying support.

  4. Oct, 20

    HanSoh Pharma closed at HK$34.38, up 8.32%, bucking a Hang Seng that fell more than 1%, after it signed an ADC licensing deal with Roche carrying a US$400 million upfront payment and potential milestone payments exceeding US$15 billion; Nomura then upgraded the shares to Buy and Goldman Sachs set a HK$52.7 target. The session traced a higher-opening, grinding uptrend: after dipping to HK$33.32 at 10:17 BJ, the stock climbed to HK$34.78 at 15:07 BJ before easing into the close, on turnover of HK$1.208 billion. Fundamentals corroborate the move, with Q2 2026 revenue of HK$4.796 billion, up 17.75% yoy, net profit of HK$2.459 billion, up 43.17%, a 51.28% net margin and EPS of HK$0.405, up 40.44%. Still, the shares sit roughly 22% below the January 14 52-week high of HK$44.22 and are down 5.65% year-to-date, having only just reclaimed the MA20 (HK$33.35) and MA60 (HK$33.56) at a PE of 27.11x.

  5. Oct, 8

    AstraZeneca's legal challenge to Aumolertinib's EU approval still overhangs, and with the HSI closing down 150 points, Hansoh Pharma spiked and faded: it touched HK$34.40 in the morning before sliding to HK$32.12 late in the afternoon session and closing at HK$32.18, down 1.74% from the prior close of HK$33.92 on HK$403mn turnover. Fundamentals contrast with the tape: Q2 2026 revenue rose 17.79% yoy to HK$4.79bn, net profit climbed 43.22% to HK$2.46bn, net margin was 51.28%, EPS rose 40.49% to HK$0.4047 and ROE stood at 22.55%. Yet the shares remain below MA20 of HK$34.07 and MA60 of HK$33.65, down 11.69% year-to-date, 27.23% under the 52-week high of HK$44.22 and only 14.68% above the June low of HK$28.06, on a P/E of 25.38x. The EASD presentation of Phase III data showing 19.3% weight loss at week 48 for olatorepatide 15 mg, an NMPA priority review for HS-20093 and HSBC's top-pick stance are medium-term threads; though EU approval uncertainty is not yet resolved.

News

Bullish vs. Bearish — Last 3 Months

3.6k followers · 0 opinions
▲Bullish50%
50%Bearish▼